Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.

The article "Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy," was originally published electronically on the publisher's internet portal without open access.

Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.

Purpose: Early identification of aggressive disease could improve decision support in pancreatic neuroendocrine tumor (pNET) patients prior to peptide receptor radionuclide therapy (PRRT). The prognostic value of intratumoral textural features (TF) determined by baseline somatostatin receptor (SSTR)-positron emission tomography (PET) before PRRT was analyzed.

Procedures: Thirty-one patients with G1/G2 pNET were enrolled (G2, n = 23/31).

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.

The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the prognostic value of tumor heterogeneity as assessed by somatostatin receptor (SSTR)-PET/CT. 141 patients with SSTR-expressing tumors were analyzed obtaining SSTR-PET/CT before PRRT (1-6 cycles, 177Lu somatostatin analog).

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.

Tyrosine kinase inhibitors (TKIs) such as vandetanib have shown clinical effectiveness in advanced medullary thyroid cancer (MTC). During TKI treatment, fluctuations in the tumor markers carcinoembryonic antigen (CEA) and calcitonin (CTN) are frequently observed. Their role for treatment monitoring and the decision-making process has not been fully elucidated yet.

Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?

Objective: A pretherapeutic assessment of kidney function before peptide receptor radionuclide therapy (PRRT) is considered essential because of the potential renal toxicity associated with PRRT. The aim of this study was to investigate the diagnostic performance of laboratory testing and Tc-mercaptoacetyltriglycine (MAG3) renal scintigraphy with a focus on patients treated with PRRT.

Materials And Methods: From January to December 2013 the kidney function of 152 patients was assessed using laboratory tests [creatinine, blood urea nitrogen (BUN), and glomerular filtration rate (GFR)] and Tc-MAG3 clearance.

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy.

Background: Peptide receptor radionuclide therapy (PRRT) is applied in patients with advanced neuroendocrine tumors. Co-infused amino acids (AA) should prevent nephrotoxicity. The aims of this study were to correlate the incidence of AA-induced hyperkalemia (HK) (≥5.

Limitations of polyethylene glycol precipitation assays for circulating immune complexes.

Polyethylene glycol precipitation assays (PEG-A) have been promoted as technically simple, inexpensive methods for detecting and quantitating circulating immune complexes; however, their specificity and sensitivity have not been clearly defined. Data are presented showing that the percent recovery of IgG in 3.5% PEG increases as the concentration of IgG increases such that hypergammaglobulinemia alone can cause a positive test result.